Terms: = Bone cancer AND ASXL1, ENSG00000171456, 171023, Q8IXJ9, MGC71111, MGC117280, KIAA0978 AND Clinical Outcome
8 results:
1. Predicting cytopenias, progression, and survival in patients with clonal cytopenia of undetermined significance: a prospective cohort study.
Cargo C; Bernard E; Beinortas T; Bolton KL; Glover P; Warren H; Payne D; Ali R; Khan A; Short M; Van Hoppe S; Smith A; Taylor J; Evans P; Papaemmanuil E; Crouch S
Lancet Haematol; 2024 Jan; 11(1):e51-e61. PubMed ID: 38135373
[TBL] [Abstract] [Full Text] [Related]
2. clinical implications of myeloid malignancy‑related somatic mutations in aplastic anemia.
Liu L; Zhang D; Fu Q; Wang J; Yu J; Chen D; Wang F; Guo R; Xie X; Jiang Z; Li Y
Clin Exp Med; 2023 Dec; 23(8):4473-4482. PubMed ID: 37087521
[TBL] [Abstract] [Full Text] [Related]
3. clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML.
Tsai CH; Tang JL; Tien FM; Kuo YY; Wu DC; Lin CC; Tseng MH; Peng YL; Hou MF; Chuang YK; Liu MC; Liu CW; Yao M; Lin LI; Chou WC; Chen CY; Hou HA; Tien HF
Blood Adv; 2021 May; 5(10):2456-2466. PubMed ID: 33999144
[TBL] [Abstract] [Full Text] [Related]
4. Cytologic features of blastic plasmacytoid dendritic cell neoplasm involving liver: A case report and literature review.
Ding Y; Yang J; Lindsey K
Diagn Cytopathol; 2021 Feb; 49(2):E80-E83. PubMed ID: 32852895
[TBL] [Abstract] [Full Text] [Related]
5. Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study.
Rogers HJ; Wang X; Xie Y; Davis AR; Thakral B; Wang SA; Borthakur G; Cantu MD; Margolskee EM; Philip JKS; Sukhanova M; Bagg A; Bueso-Ramos CE; Orazi A; Arber DA; Hsi ED; Hasserjian RP
Am J Hematol; 2020 Jul; 95(7):799-808. PubMed ID: 32249963
[TBL] [Abstract] [Full Text] [Related]
6. [Research on molecular markers for epigenetic changes in myeloid malignancies].
Li L; Sun XM
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Dec; 30(6):687-92. PubMed ID: 24327148
[TBL] [Abstract] [Full Text] [Related]
7. Mutations in asxl1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.
Gelsi-Boyer V; Brecqueville M; Devillier R; Murati A; Mozziconacci MJ; Birnbaum D
J Hematol Oncol; 2012 Mar; 5():12. PubMed ID: 22436456
[TBL] [Abstract] [Full Text] [Related]
8. Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices.
Tefferi A
Leuk Lymphoma; 2010 Apr; 51(4):576-82. PubMed ID: 20214447
[TBL] [Abstract] [Full Text] [Related]
